Searchable abstracts of presentations at key conferences in endocrinology

ea0031s1.2 | Irn bru, to drink or not to drink: endocrinology and iron | SFEBES2013

The iron-regulatory hormone hepcidin

Nemeth Elizabeta

The hepatic peptide hormone hepcidin is the principal regulator of iron absorption and tissue iron distribution. Hepcidin circulates in blood plasma and acts at nanomolar concentrations by inducing degradation of its receptor, the cellular iron exporter ferroportin. Ferroportin exports iron into plasma from absorptive enterocytes, from macrophages that recycle the iron of senescent erythrocytes, and from hepatocytes that store iron. Therefore, hepcidin-mediated degradation of ...

ea0002sp20 | <emphasis>Journal of Molecular Endocrinology</emphasis> Symposium: Receptor Antagonists | SFE2001

Calcium Receptor Antagonists

Nemeth E

The cell surface calcium receptor is the primary molecular entity regulating secretion of parathyroid hormone (PTH). Activation of this receptor by extracellular calcium inhibits PTH secretion whereas blocking the calcium receptor stimulates secretion of PTH. Chronically elevated levels of PTH, as occurs in hyperparathyroidism, stimulate bone resorption whereas temporary increases in circulating levels of PTH stimulate bone formation. This stimulatory effect on bone has prompt...

ea0002p46 | Genetics | SFE2001

Klinefelter-like phenotype and primary infertility in a male with an Xq inversion

Gallen I , Levy E , Crocker M , Maher E , Nemeth A

Klinefelter syndrome is an abnormality of sexual development which is usually characterised by the chromosome complement of 47,XXY, although occasionally patients may have multiple X or Y chromosomes, may be mosaic with 46, XY, 47,XXY or have an X-autosome translocation. We present the case of a 43 year old male patient with the phenotypic appearance of Klinefelter syndrome and primary infertility, who was found on karyotype analysis to have an hitherto undescribed inversion o...

ea0063p711 | Pituitary and Neuroendocrinology 2 | ECE2019

Whole genome demethylation status of somatic DNA extracted from different pituitary adenoma types

Szabo Borbala , Nemeth Kinga , Meszaros Katalin , Szucs Nikolett , Czirjak Sandor , Reiniger Lilla , Patocs Attila , Butz Henriett

Background: Although the role of hypermethylation of certain tumor suppressor genes are known in pituitary adenomas little information is available regarding whole methylation-demethylation status and especially regarding its correlation with clinical parameters. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) is an easy and accurate method to detect the level of methylcytosine (5 mC) and the demethylation intermedier hydroxymethylcytosine (5 hmC) ...

ea0049gp44 | Bone & Calcium Homeostasis 2 | ECE2017

Investigation of total and free 25OHD vitamin levels in patients with chronic renal failure on different dose of cholecalciferol

Toldy Erzsebet , Kovacs Laszlo , Nemeth Reka , Szakacs Gyulane , Kulcsar Imre , Locsei Zoltan

The total 25-hydroxy-vitamin-D (t-25OHD) level reflects the vitamin-D supply, but it is also influenced by the levels of vitamin-D-binding-proteins (DBP) and albumin. The type of dialysis influences the levels of serum proteins. The ‘free-hormone hypothesis’ states that only the free molecules (f25OHD) can diffuse intracellular. Our aim was to evaluate the total, calculated (c-f25OHD) and direct measured (dm-f25OHD) 25OHD levels in patients with chronic renal disease...

ea0090rc8.4 | Rapid Communications 8: Calcium and Bone | ECE2023

Encaleret (CLTX-305) normalized mineral homeostasis parameters in patients with autosomal dominant hypocalcemia type 1: Results over 12 months in a phase 2 study (NCT04581629)

Collins Michael , Hartley Iris , Roszko Kelly , Nemeth Edward , Pozo Karen , Boykin Winsome , Mathew Arun , Roberts Mary Scott , Adler Scott

Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. Conventional therapy (calcium and active vitamin D) worsens hypercalciuria, which may result in renal complications. Calcilytics, such as encaleret, are negative allosteric modulators of the calcium-sensing receptor (CaSR). T...

ea0044p44 | Bone and Calcium | SFEBES2016

The calcilytic SHP635 rectifies hypocalcaemia and reduced parathyroid hormone concentrations in a mouse model for autosomal dominant hypocalcaemia type 1 (ADH1)

Hannan Fadil , Babinsky Valerie , Gorvin Caroline , Hough Tertius , Joynson Elizabeth , Stewart Michelle , Wells Sara , Cox Roger , Nemeth Edward , Thakker Rajesh

Autosomal dominant hypocalcaemia type 1 (ADH1) is a systemic disorder of calcium homeostasis caused by gain-of-function mutations of the calcium-sensing receptor (CaSR). ADH1 may lead to symptomatic hypocalcaemia, inappropriately low parathyroid hormone (PTH) concentrations and hypercalciuria. Active vitamin D metabolites are the mainstay of treatment for symptomatic ADH1 patients, however their use predisposes to nephrocalcinosis, nephrolithiasis and renal impairment. Calcily...

ea0037ep314 | Calcium and Vitamin D metabolism | ECE2015

Idiopathic hypercalcaemia in pregnancy not due to PTHrP: suggestion for another pathomechanism by genetic defect of 24-hydroxylase

Horvath Csaba , Meszaros Szilvia , Acs Orsolya , Hosszu Eva , Nemeth Julia , Csupor Emoke , Szathmari Miklos , Acs Nandor , McCloskey Eugene V

A 32-year-old women initially presented with recurrent kidney stones and was found to have nephrocalcinosis. She was found to normocalcaemic but hypercalciuric, with a plasma ionized calcium at upper-limit of normal and a PTH in lower normal range. One year later, during the first trimester of a pregnancy, she presented with severe hypercalcaemia, hypercalciuria and suppression of PTH. Extensive investigations for causes of hypercalcaemia excluded hyperparathyroidism, other en...

ea0056p779 | Pituitary - Basic | ECE2018

Next generation sequencing for characterization of mitochondrial genome in pituitary adenomas

Nemeth Kinga , Darvasi Otto , Liko Istvan , Szucs Nikolette , Czirjak Sandor , Reiniger Lilla , Szabo Borbala , Igaz Peter , Patocs Attila , Butz Henriett

Introduction: Disrupted mitochondrial functions and genetic variations of mitochondrial DNA (mtDNA) have been observed in different tumors. Regarding pituitary adenomas mtDNA was evaluated only in oncocytic type using PCR based methods and it showed high prevalence of Complex I variants. Next generation sequencing (NGS) allows high throughput sequencing and it is useful for accurate identification of heteroplasmy of mitochondrial genome as well.Aim: We a...

ea0081rc8.2 | Rapid Communications 8: Calcium and Bone | ECE2022

Temporal effects of encaleret (CLTX-305) on mineral physiology in autosomal dominant hypocalcemia type 1 (ADH1): results from a phase 2B, open-label, dose-ranging study [NCT04581629]

Gafni Rachel , Hartley Iris , Roszko Kelly , Pozo Karen , Nemeth Edward , Sani-Grosso Ramei , Mathew Arun , Sridhar Ananth , Scott Roberts Mary , Fox Jonathan , Collins Michael

Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function variants in the calcium-sensing receptor (CaSR, gene: CASR) and is characterized by hypocalcemia, hyperphosphatemia, low parathyroid hormone (PTH), and hypercalciuria. Calcilytics (negative allosteric modulators of the CaSR) decrease the sensitivity of activated receptors to extracellular calcium and normalize blood and urine abnormalities in ADH1 rodent models. Encaleret is an oral calcilytic u...